MedTrace Logo

e-NOBORI Observational Registry of Nobori DES

NCT01261273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18000

Last updated 2019-10-09

No results posted yet for this study

Summary

Title Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the Nobori® DES in real-world patients.

Objective Primary objective The primary objective of e-NOBORI registry is to further validate the safety and efficacy of Nobori® DES system in unselected patients representing everyday clinical practice.

Primary Endpoint: Freedom from Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 1 year

Conditions

Sponsors & Collaborators

  • Terumo Europe N.V.

    lead INDUSTRY

Principal Investigators

  • Dragica Paunovic, Dr. · Terumo Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-25
Primary Completion
2016-05-31
Completion
2016-05-27

Countries

  • Austria
  • Bangladesh
  • Belarus
  • Brazil
  • Bulgaria
  • Chile
  • Czechia
  • Denmark
  • Egypt
  • Estonia
  • France
  • Georgia
  • Germany
  • Hungary
  • Indonesia
  • Ireland
  • Israel
  • Latvia
  • Lithuania
  • Malta
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovenia
  • Spain
  • Sweden
  • Taiwan
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01261273 on ClinicalTrials.gov